BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14697794)

  • 1. Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure.
    Mimoto T; Terashima K; Nojima S; Takaku H; Nakayama M; Shintani M; Yamaoka T; Hayashi H
    Bioorg Med Chem; 2004 Jan; 12(1):281-93. PubMed ID: 14697794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
    Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
    Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
    Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
    J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel dipeptide-based HIV protease inhibitor containing allophenylnorstatine.
    Abdel-Rahman HM; el-Koussi NA; Alkaramany GS; Youssef AF; Kiso Y
    Arch Pharm (Weinheim); 2004 Nov; 337(11):587-98. PubMed ID: 15540219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
    Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
    J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
    Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
    J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere.
    Mimoto T; Hattori N; Takaku H; Kisanuki S; Fukazawa T; Terashima K; Kato R; Nojima S; Misawa S; Ueno T; Imai J; Enomoto H; Tanaka S; Sakikawa H; Shintani M; Hayashi H; Kiso Y
    Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1310-26. PubMed ID: 10993230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.
    Le VD; Mak CC; Lin YC; Elder JH; Wong CH
    Bioorg Med Chem; 2001 May; 9(5):1185-95. PubMed ID: 11377177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine.
    Hidaka K; Kimura T; Sankaranarayanan R; Wang J; McDaniel KF; Kempf DJ; Kameoka M; Adachi M; Kuroki R; Nguyen JT; Hayashi Y; Kiso Y
    J Med Chem; 2018 Jun; 61(12):5138-5153. PubMed ID: 29852069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.
    Kageyama S; Mimoto T; Murakawa Y; Nomizu M; Ford H; Shirasaka T; Gulnik S; Erickson J; Takada K; Hayashi H
    Antimicrob Agents Chemother; 1993 Apr; 37(4):810-7. PubMed ID: 8494379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
    Perryman AL; Lin JH; Andrew McCammon J
    Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic.
    Mimoto T; Imai J; Tanaka S; Hattori N; Takahashi O; Kisanuki S; Nagano Y; Shintani M; Hayashi H; Sakikawa H
    Chem Pharm Bull (Tokyo); 1991 Sep; 39(9):2465-7. PubMed ID: 1804562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine.
    Baldwin ET; Bhat TN; Gulnik S; Liu B; Topol IA; Kiso Y; Mimoto T; Mitsuya H; Erickson JW
    Structure; 1995 Jun; 3(6):581-90. PubMed ID: 8590019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.
    Yoshimura K; Kato R; Yusa K; Kavlick MF; Maroun V; Nguyen A; Mimoto T; Ueno T; Shintani M; Falloon J; Masur H; Hayashi H; Erickson J; Mitsuya H
    Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8675-80. PubMed ID: 10411934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site.
    Takashiro E; Watanabe T; Nitta T; Kasuya A; Miyamoto S; Ozawa Y; Yagi R; Nishigaki T; Shibayama T; Nakagawa A; Iwamoto A; Yabe Y
    Bioorg Med Chem; 1998 May; 6(5):595-604. PubMed ID: 9629473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere.
    Kiso Y
    Biopolymers; 1996; 40(2):235-44. PubMed ID: 8785365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine.
    Mimoto T; Imai J; Kisanuki S; Enomoto H; Hattori N; Akaji K; Kiso Y
    Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2251-3. PubMed ID: 1423795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties.
    Ami E; Nakahara K; Sato A; Nguyen JT; Hidaka K; Hamada Y; Nakatani S; Kimura T; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4213-7. PubMed ID: 17537628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic.
    Mimoto T; Imai J; Tanaka S; Hattori N; Kisanuki S; Akaji K; Kiso Y
    Chem Pharm Bull (Tokyo); 1991 Nov; 39(11):3088-90. PubMed ID: 1799953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
    Surleraux DL; Tahri A; Verschueren WG; Pille GM; de Kock HA; Jonckers TH; Peeters A; De Meyer S; Azijn H; Pauwels R; de Bethune MP; King NM; Prabu-Jeyabalan M; Schiffer CA; Wigerinck PB
    J Med Chem; 2005 Mar; 48(6):1813-22. PubMed ID: 15771427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.